Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I

• Type: Another Publication in an International Scientific Journal
• Date: 2019

Authors

Vieira, R (Author) Other; Souto, SB (Author) Other; Sanchez Lopez, E (Author) Other; Machado, AL (Author) Other; Severino, P (Author) Other; Jose, S (Author) Other; Santini, A (Author) Other; Fortuna, A (Author) Other; Garcia, ML (Author) Other; Silva, AM (Author) Other; Souto, EB (Author) Other

Journal

Title: Pharmaceuticals

Vol. 12

Final page: 152

ISSN: 1424-8247

Publisher: MDPI

Indexing

ISI Web of Knowledge - 46 Citations

Scopus - 51 Citations

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00R-6T0

DOI: 10.3390/ph12040152

Abstract (EN): Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 31